{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:12:20Z","timestamp":1788232340953,"version":"build-2803163510"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019305","name":"Manipal Academy of Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019305","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.intimp.2022.109597","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T12:12:13Z","timestamp":1674562333000},"page":"109597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Thiopurine therapy in inflammatory bowel disease in the pandemic era: Safe or unsafe?"],"prefix":"10.1016","volume":"116","author":[{"given":"Shailesh","family":"Perdalkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Basthi Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Musunuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddheesh","family":"Rajpurohit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiran","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnamurthy","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cannanore Ganesh","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.intimp.2022.109597_b0005","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1007\/s10620-020-06662-z","article-title":"Evolving Role of Thiopurines in Inflammatory Bowel Disease in the Era of Biologics and New Small Molecules","volume":"66","author":"Nguyen","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.intimp.2022.109597_b0010","first-page":"17","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet","volume":"5","author":"Alatab","year":"2020","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2022.109597_b0015","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.3748\/wjg.v20.i12.3146","article-title":"Immunosuppressive therapies for inflammatory bowel disease","volume":"20","author":"Zenlea","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.intimp.2022.109597_b0020","article-title":"Treatment of Inflammatory Bowel Disease: A Comprehensive Review","volume":"8","author":"Cai","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"10.1016\/j.intimp.2022.109597_b0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/JIR.S165330","article-title":"Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives","volume":"11","author":"Rawla","year":"2018","journal-title":"J. Inflamm. Res."},{"issue":"11","key":"10.1016\/j.intimp.2022.109597_b0030","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3748\/wjg.v27.i11.1022","article-title":"How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician","volume":"27","author":"Chebli","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.intimp.2022.109597_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105075","article-title":"Inflammatory Bowel Disease \u2013 Non-biological treatment","volume":"160","author":"Magro","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2022.109597_b0040","first-page":"1","article-title":"De-escalation of IBD Therapy: When, Who, and How?","volume":"360","author":"Waljee","year":"2019","journal-title":"Crohns Colitis"},{"key":"10.1016\/j.intimp.2022.109597_b0045","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000458006","article-title":"Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease","volume":"33","author":"Atreya","year":"2017","journal-title":"Visc Med."},{"issue":"4","key":"10.1016\/j.intimp.2022.109597_b0050","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/rheumatology\/keab615","article-title":"The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19","volume":"61","author":"Orlandi","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2022.109597_b0055","doi-asserted-by":"crossref","unstructured":"M. Bonato, P. Peditto, N. Landini, A. Fraccaro, C. Catino, M. Cuzzola, N. Malacchini, F. Savoia, N. Roma, M. Salasnich, M. Turrin, F. Zampieri, G. Zanardi, F. Zeraj, M. Rattazzi, M. Peta, S. Baraldo, M. Saetta, M. Fusaro, G. Morana, M. Romagnoli, Multidimensional 3-Month Follow-Up of Severe COVID-19: Airways beyond the Parenchyma in Symptomatic Patients, Journal of Clinical Medicine 2022, Vol. 11, Page 4046. 11 (2022) 4046. https:\/\/doi.org\/10.3390\/JCM11144046.","DOI":"10.3390\/jcm11144046"},{"key":"10.1016\/j.intimp.2022.109597_b0060","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.dld.2020.09.002","article-title":"COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data","volume":"52","author":"Macaluso","year":"2020","journal-title":"Dig. Liver Dis."},{"issue":"5","key":"10.1016\/j.intimp.2022.109597_b0065","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1159\/000510502","article-title":"Expert opinions on the current therapeutic management of inflammatory bowel disease during the covid-19 pandemic: Japan ibd covid-19 taskforce, intractable diseases, the health and labor sciences research","volume":"102","author":"Nakase","year":"2021","journal-title":"Digestion"},{"key":"10.1016\/j.intimp.2022.109597_b0070","doi-asserted-by":"crossref","unstructured":"L.E. Targownik, C.N. Bernstein, P.L. Lakatos, S.K. Murthy, E.I. Benchimol, A. Bitton, J.G. Huang, M.E. Kuenzig, J.L. Jones, G.G. Kaplan, K. Lee, M.S. Mukhtar, P. Tandon, J.W. Windsor, R. Panaccione, Crohn\u2019s and Colitis Canada\u2019s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Risk Factors and Medications, J Can Assoc Gastroenterol. 4 (2021) S40\u2013S45. https:\/\/doi.org\/10.1093\/JCAG\/GWAB032.","DOI":"10.1093\/jcag\/gwab032"},{"issue":"4","key":"10.1016\/j.intimp.2022.109597_b0075","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/jgh.15241","article-title":"A review on medical management of inflammatory bowel disease during the coronavirus disease 2019 pandemic","volume":"36","author":"Chela","year":"2021","journal-title":"Journal of Gastroenterology and Hepatology (Australia)."},{"key":"10.1016\/j.intimp.2022.109597_b0080","doi-asserted-by":"crossref","unstructured":"M.H. Rosen, J. Axelrad, D. Hudesman, D.T. Rubin, S. Chang, Management of Acute Severe Ulcerative Colitis in a Pregnant Woman with COVID-19 Infection: A Case Report and Review of the Literature, Inflamm Bowel Dis. 26 (2020) 971\u2013973. https:\/\/doi.org\/10.1093\/ibd\/izaa109.","DOI":"10.1093\/ibd\/izaa109"},{"key":"10.1016\/j.intimp.2022.109597_b0085","doi-asserted-by":"crossref","unstructured":"M. Dave, T. Purohit, R. Razonable, E. v. Loftus, Opportunistic infections due to inflammatory bowel disease therapy, Inflamm Bowel Dis. 20 (2014) 196\u2013212. https:\/\/doi.org\/10.1097\/MIB.0B013E3182A827D2.","DOI":"10.1097\/MIB.0b013e3182a827d2"},{"issue":"18","key":"10.1016\/j.intimp.2022.109597_b0090","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.3748\/wjg.v25.i18.2240","article-title":"Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"25","author":"Gong","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.intimp.2022.109597_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.01333","article-title":"Immunosuppressive Drugs and COVID-19: A Review","volume":"11","author":"Schoot","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2022.109597_b0100","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.3389\/fphar.2020.582291","article-title":"Thiopurines: Recent Topics and Their Role in the Treatment of Inflammatory Bowel Diseases","volume":"11","author":"Tominaga","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2022.109597_b0105","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/gutjnl-2019-320185","article-title":"Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn\u2019s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource","volume":"70","author":"Stournaras","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2022.109597_b0110","first-page":"1","article-title":"Azathioprine with Allopurinol Is a Promising First-Line Therapy for Inflammatory Bowel Diseases","volume":"1","author":"van Liere","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.intimp.2022.109597_b0115","doi-asserted-by":"crossref","first-page":"524","DOI":"10.4292\/wjgpt.v7.i4.524","article-title":"How I treat my inflammatory bowel disease-patients with thiopurines?","volume":"7","author":"Meijer","year":"2016","journal-title":"World J Gastrointest Pharmacol Ther."},{"key":"10.1016\/j.intimp.2022.109597_b0120","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1365-2036.2008.03732.x","article-title":"Comparative effectiveness of azathioprine in Crohn\u2019s disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients","volume":"28","author":"Gisbert","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2022.109597_b0125","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1007\/s10620-018-5381-0","article-title":"Usefulness of Thiopurine Monotherapy for Crohn\u2019s Disease in the Era of Biologics: A Long-Term Single-Center Experience","volume":"64","author":"Su\u00e1rez Ferrer","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.intimp.2022.109597_b0130","doi-asserted-by":"crossref","first-page":"7795","DOI":"10.3748\/wjg.v21.i25.7795","article-title":"Clinical predictors of thiopurine-related adverse events in Crohn\u2019s disease","volume":"21","author":"Moran","year":"2015","journal-title":"World J Gastroenterol: WJG"},{"key":"10.1016\/j.intimp.2022.109597_b0135","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-021-01900-8","article-title":"TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India","volume":"21","author":"Grover","year":"2021","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.intimp.2022.109597_b0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-87095-0","article-title":"Association of genetic variants in TPMT, ITPA, and NUDT15 with azathioprine-induced myelosuppression in southwest china patients with autoimmune hepatitis","volume":"11","author":"Miao","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.intimp.2022.109597_b0145","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/2040622315579063","article-title":"Optimizing the use of thiopurines in inflammatory bowel disease","volume":"6","author":"Goel","year":"2015","journal-title":"Ther Adv Chronic Dis."},{"key":"10.1016\/j.intimp.2022.109597_b0150","volume":"8","author":"Gargallo-Puyuelo","year":"2021","journal-title":"Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era?, Front Med (Lausanne)."},{"key":"10.1016\/j.intimp.2022.109597_b0155","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/1744666X.2017.1351298","article-title":"Optimising use of thiopurines in inflammatory bowel disease","volume":"13","author":"Dart","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.intimp.2022.109597_b0160","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3389\/fphar.2018.01107","article-title":"Revisiting the role of thiopurines in inflammatory bowel disease through pharmacogenomics and use of novel methods for therapeutic drug monitoring","volume":"9","author":"Lim","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2022.109597_b0165","doi-asserted-by":"crossref","DOI":"10.21037\/tgh.2019.11.09","article-title":"NUDT15 genotyping in Caucasian patients can help to optimise thiopurine treatment in patients with inflammatory bowel disease","volume":"4","author":"Coenen","year":"2019","journal-title":"Transl Gastroenterol Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109597_b0170","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2022.109597_b0175","doi-asserted-by":"crossref","first-page":"10103","DOI":"10.3748\/wjg.v22.i46.10103","article-title":"Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective","volume":"22","author":"Axelrad","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.intimp.2022.109597_b0180","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis","volume":"2016","author":"Timmer","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.intimp.2022.109597_b0185","article-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn\u2019s disease","volume":"2016","author":"Chande","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.intimp.2022.109597_b0190","first-page":"1","article-title":"Thiopurine Monotherapy Is Effective in Maintenance of Mild-Moderate Inflammatory Bowel Disease","volume":"1","author":"Barber","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.intimp.2022.109597_b0195","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11938-017-0130-6","article-title":"Treat to Target in Inflammatory Bowel Disease: An Updated Review of Literature","volume":"15","author":"Darr","year":"2017","journal-title":"Curr Treat Options Gastroenterol."},{"key":"10.1016\/j.intimp.2022.109597_b0200","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/ecco-jcc\/jjz131","article-title":"Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review","volume":"14","author":"Colombel","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.intimp.2022.109597_b0205","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ibd.20777","article-title":"Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn\u2019s disease","volume":"15","author":"Mantzaris","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.intimp.2022.109597_b0210","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.109597_b0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5217\/ir.2020.00155","article-title":"Use of thiopurines in inflammatory bowel disease: an update","volume":"20","author":"Singh","year":"2022","journal-title":"Intest Res."},{"key":"10.1016\/j.intimp.2022.109597_b0220","article-title":"Discussion","volume":"24","author":"Kahn","year":"2005","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"3","key":"10.1016\/j.intimp.2022.109597_b0225","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.intimp.2022.109597_b0230","doi-asserted-by":"crossref","unstructured":"A.E. Gorbalenya, S.C. Baker, R.S. Baric, R.J. de Groot, C. Drosten, A.A. Gulyaeva, B.L. Haagmans, C. Lauber, A.M. Leontovich, B.W. Neuman, D. Penzar, S. Perlman, L.L.M. Poon, D. Samborskiy, I.A. Sidorov, I. Sola, J. Ziebuhr, Severe acute respiratory syndrome-related coronavirus: The species and its viruses \u2013 a statement of the Coronavirus Study Group, BioRxiv. (2020). https:\/\/doi.org\/10.1101\/2020.02.07.937862.","DOI":"10.1101\/2020.02.07.937862"},{"key":"10.1016\/j.intimp.2022.109597_b0235","unstructured":"K. Mcintosh, Coronavirus disease 2019 (COVID-19): Epidemiology, virology, and prevention, n.d. www.uptodate.com."},{"key":"10.1016\/j.intimp.2022.109597_b0240","unstructured":"WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data, (n.d.). https:\/\/covid19.who.int\/ (accessed December 2, 2022)."},{"key":"10.1016\/j.intimp.2022.109597_b0245","doi-asserted-by":"crossref","unstructured":"R. Lu, X. Zhao, J. Li, P. Niu, B. Yang, H. Wu, W. Wang, H. Song, B. Huang, N. Zhu, Y. Bi, X. Ma, F. Zhan, L. Wang, T. Hu, H. Zhou, Z. Hu, W. Zhou, L. Zhao, J. Chen, Y. Meng, J. Wang, Y. Lin, J. Yuan, Z. Xie, J. Ma, W.J. Liu, D. Wang, W. Xu, E.C. Holmes, G.F. Gao, G. Wu, W. Chen, W. Shi, W. Tan, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, The Lancet. 395 (2020) 565\u2013574. https:\/\/doi.org\/10.1016\/S0140-6736(20)30251-8.","DOI":"10.1016\/S0140-6736(20)30251-8"},{"key":"10.1016\/j.intimp.2022.109597_b0250","article-title":"Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update","volume":"12","author":"Pal","year":"2020","journal-title":"Cureus."},{"key":"10.1016\/j.intimp.2022.109597_b0255","doi-asserted-by":"crossref","unstructured":"A.E. Gorbalenya, S.C. Baker, R.S. Baric, R.J. de Groot, C. Drosten, A.A. Gulyaeva, B.L. Haagmans, C. Lauber, A.M. Leontovich, B.W. Neuman, D. Penzar, S. Perlman, L.L. M Poon, D. v Samborskiy, I.A. Sidorov, I. Sola, J. Ziebuhr, The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, (n.d.). https:\/\/doi.org\/10.1038\/s41564-020-0695-z.","DOI":"10.1038\/s41564-020-0695-z"},{"key":"10.1016\/j.intimp.2022.109597_b0260","article-title":"Virology, transmission, and pathogenesis of SARS-CoV-2","volume":"371","author":"Cevik","year":"2020","journal-title":"The BMJ."},{"key":"10.1016\/j.intimp.2022.109597_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-020-01402-1","article-title":"Characterization of accessory genes in coronavirus genomes","volume":"17","author":"Michel","year":"2020","journal-title":"Virol. J."},{"key":"10.1016\/j.intimp.2022.109597_b0270","doi-asserted-by":"crossref","unstructured":"I. Jungreis, R. Sealfon, M. Kellis, SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes, Nature Communications 2021 12:1. 12 (2021) 1\u201320. https:\/\/doi.org\/10.1038\/s41467-021-22905-7.","DOI":"10.1038\/s41467-021-22905-7"},{"issue":"5","key":"10.1016\/j.intimp.2022.109597_b0275","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41423-020-0407-x","article-title":"COVID-19: a new challenge for human beings","volume":"17","author":"Yang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2022.109597_b0280","doi-asserted-by":"crossref","first-page":"112816","DOI":"10.1016\/j.envres.2022.112816","article-title":"Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic","volume":"209","author":"Khandia","year":"2022","journal-title":"Environ. Res."},{"key":"10.1016\/j.intimp.2022.109597_b0285","unstructured":"Cascella M, Rajnik M, Cuomo A, Features, Evaluation, and Treatment of Coronavirus (COVID-19) Continuing Education Activity, (n.d.). Cascella M, Rajnik M, Aleem A, Dulebohn S, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls. 2022 Jan 5. (accessed January 31, 2022)."},{"key":"10.1016\/j.intimp.2022.109597_b0290","doi-asserted-by":"crossref","unstructured":"I. Guerra, A. Algaba, L. Jim\u00e9nez, M.M. Aller, D. Garza, D. Bonillo, L.M.M. Esteban, F. Bermejo, Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients with Inflammatory Bowel Disease: A Single-Center Study in Madrid, Spain, Inflamm Bowel Dis. 27 (2021) 25\u201333. https:\/\/doi.org\/10.1093\/ibd\/izaa221.","DOI":"10.1093\/ibd\/izaa221"},{"key":"10.1016\/j.intimp.2022.109597_b0295","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.12998\/wjcc.v8.i18.3934","article-title":"Gastrointestinal insights during the COVID-19 epidemic","volume":"8","author":"Nie","year":"2020","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.intimp.2022.109597_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104351","article-title":"Emergence of genomic diversity and recurrent mutations in SARS-CoV-2","volume":"83","author":"van Dorp","year":"2020","journal-title":"Infect. Genet. Evol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109597_b0305","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41563-020-00906-z","article-title":"Diagnostics for SARS-CoV-2 infections","volume":"20","author":"Kevadiya","year":"2021","journal-title":"Nat. Mater."},{"key":"10.1016\/j.intimp.2022.109597_b0310","doi-asserted-by":"crossref","unstructured":"M. Shirzad, M. Nourigorji, A. Sajedi, M. Ranjbar, F. Rasti, Z. Sourani, M. Moradi, S. Mostafa Mir, M.Y. Memar, Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine, Int Immunopharmacol. 111 (2022) 109161. https:\/\/doi.org\/10.1016\/J.INTIMP.2022.109161.","DOI":"10.1016\/j.intimp.2022.109161"},{"key":"10.1016\/j.intimp.2022.109597_b0315","doi-asserted-by":"crossref","unstructured":"D. Shin, R. Mukherjee, D. Grewe, K. Baek, A. Bhattacharya, L. Schulz, M. Widera, A.R. Mehdipour, G. Tascher, P.P. Geurink, Inhibition of papain-like protease PLpro blocks SARS-CoV-2 spread and promotes anti-viral immunity, (n.d.). https:\/\/doi.org\/10.21203\/rs.3.rs-27134\/v1.","DOI":"10.21203\/rs.3.rs-27134\/v1"},{"key":"10.1016\/j.intimp.2022.109597_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106924","article-title":"Immunotherapeutic approaches to curtail COVID-19","volume":"88","author":"Owji","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2022.109597_b0325","doi-asserted-by":"crossref","first-page":"15189","DOI":"10.1128\/JVI.79.24.15189-15198.2005","article-title":"The Papain-Like Protease of Severe Acute Respiratory Syndrome Coronavirus Has Deubiquitinating Activity","volume":"79","author":"Barretto","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2022.109597_b0330","doi-asserted-by":"crossref","unstructured":"G. Vere, M.R. Alam, S. Farrar, R. Kealy, B.M. Kessler, D.P. O\u2019brien, A. Pinto-Fern\u00e1ndez, Targeting the Ubiquitylation and ISGylation Machinery for the Treatment of COVID-19, Biomolecules 2022, Vol. 12, Page 300. 12 (2022) 300. https:\/\/doi.org\/10.3390\/BIOM12020300.","DOI":"10.3390\/biom12020300"},{"key":"10.1016\/j.intimp.2022.109597_b0335","doi-asserted-by":"crossref","unstructured":"J. Osipiuk, S.A. Azizi, S. Dvorkin, M. Endres, R. Jedrzejczak, K.A. Jones, S. Kang, R.S. Kathayat, Y. Kim, V.G. Lisnyak, S.L. Maki, V. Nicolaescu, C.A. Taylor, C. Tesar, Y.A. Zhang, Z. Zhou, G. Randall, K. Michalska, S.A. Snyder, B.C. Dickinson, A. Joachimiak, Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors, Nature Communications 2021 12:1. 12 (2021) 1\u20139. https:\/\/doi.org\/10.1038\/s41467-021-21060-3.","DOI":"10.1038\/s41467-021-21060-3"},{"key":"10.1016\/j.intimp.2022.109597_b0340","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.antiviral.2014.06.011","article-title":"Crystal structure of the papain-like protease of MERS coronavirus reveals unusual, potentially druggable active-site features","volume":"109","author":"Lei","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2022.109597_b0345","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1007\/s12035-021-02517-4","article-title":"NK Cell Subpopulations and Receptor Expression in Recovering SARS-CoV-2 Infection","volume":"58","author":"Saresella","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.intimp.2022.109597_b0350","article-title":"Mechanism and inhibition of SARS-CoV-2 PLpro","author":"Klemm","year":"2020","journal-title":"BioRxiv."},{"issue":"10","key":"10.1016\/j.intimp.2022.109597_b0355","doi-asserted-by":"crossref","first-page":"103213","DOI":"10.1016\/j.isci.2021.103213","article-title":"6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro","volume":"24","author":"Swaim","year":"2021","journal-title":"IScience."},{"key":"10.1016\/j.intimp.2022.109597_b0360","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds","volume":"115","author":"B\u00e1ez-Santos","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2022.109597_b0365","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.antiviral.2014.12.011","article-title":"Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus","volume":"115","author":"Cheng","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2022.109597_b0370","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.bcp.2008.01.005","article-title":"Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus","volume":"75","author":"Chou","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2022.109597_b0375","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/095632020901900402","article-title":"Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme","volume":"19","author":"Chen","year":"2009","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.intimp.2022.109597_b0380","article-title":"6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro protease activities","author":"Swaim","year":"2020","journal-title":"BioRxiv."},{"key":"10.1016\/j.intimp.2022.109597_b0385","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gutjnl-2020-322539","article-title":"Effect of IBD medications on COVID-19 outcomes: results from an international registry","volume":"70","author":"Ungaro","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2022.109597_b0390","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5217\/ir.2020.00156","article-title":"RISK OF COVID-19 IN IBD PATIENTS Management of inflammatory bowel disease in the COVID-19 era","volume":"20","author":"Kim","year":"2022","journal-title":"Intest Res."},{"issue":"1","key":"10.1016\/j.intimp.2022.109597_b0395","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.gastro.2020.04.012","article-title":"AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary","volume":"159","author":"Rubin","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2022.109597_b0400","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/gutjnl-2020-321244","article-title":"British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic","volume":"69","author":"Kennedy","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2022.109597_b0405","doi-asserted-by":"crossref","unstructured":"R. J-f, van C. der Woude, Inflammatory bowel disease management during the COVID-19 outbreak: The 10 do\u2019s and don\u2019ts from the ECCO-COVID Taskforce, (n.d.). https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa160.","DOI":"10.1093\/ecco-jcc\/jjaa160"},{"key":"10.1016\/j.intimp.2022.109597_b0410","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1159\/000510502","article-title":"Expert Opinions on the Current Therapeutic Management of Inflammatory Bowel Disease during the COVID-19 Pandemic: Japan IBD COVID-19 Taskforce, Intractable Diseases, the Health and Labor Sciences Research","volume":"102","author":"Nakase","year":"2021","journal-title":"Digestion"},{"key":"10.1016\/j.intimp.2022.109597_b0415","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jgh3.12362","article-title":"Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease (IBD) Working Party guidelines on IBD management during the COVID-19 pandemic","volume":"4","author":"Ling","year":"2020","journal-title":"JGH Open."},{"key":"10.1016\/j.intimp.2022.109597_b0420","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/gutjnl-2020-323247","article-title":"COVID-19 and IBD drugs: should we change anything at the moment?","volume":"70","author":"Lees","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2022.109597_b0425","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/MEG.0000000000002239","article-title":"Effect of inflammatory bowel disease and related medications on COVID-19 incidence, disease severity, and outcome: the Israeli experience","volume":"34","author":"Richter","year":"2022","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109597_b0430","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10238-021-00755-3","article-title":"Neither inflammatory bowel disease nor immunosuppressants are associated with an increased risk of severe COVID-19: an observational Dutch cohort study","volume":"22","author":"Gilissen","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.intimp.2022.109597_b0435","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1053\/j.gastro.2020.05.065","article-title":"Impact of Anti-Tumor Necrosis Factor and Thiopurine Medications on the Development of COVID-19 in Patients With Inflammatory Bowel Disease: A Nationwide Veterans Administration Cohort Study","volume":"159","author":"Khan","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2022.109597_b0440","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1136\/gutjnl-2020-321411","article-title":"Outcomes of COVID-19 in 79 patients with IBD in Italy: An IG-IBD study","volume":"69","author":"Bezzio","year":"2020","journal-title":"Gut"},{"issue":"11-12","key":"10.1016\/j.intimp.2022.109597_b0445","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/apt.16663","article-title":"Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study","volume":"54","author":"Bezzio","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2022.109597_b0450","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2020.05.032","article-title":"Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry","volume":"159","author":"Brenner","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2022.109597_b0455","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cgh.2020.10.010","article-title":"Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases","volume":"19","author":"Brenner","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2022.109597_b0460","unstructured":"L. SCUCCHI, B. NERI, L. SARMATI, M. MOSSA, G. SENA, R. MASSOUD, C. PETRUZZIELLO, M. MUSUMECI, I. MARAFINI, E. CALABRESE, E. LOLLI, S. BERNARDINI, M. ANDREONI, G. MONTELEONE, L. BIANCONE, Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease, Eur Rev Med Pharmacol Sci. 25 (2021) 2418\u20132424. https:\/\/doi.org\/10.26355\/eurrev_202103_25283."},{"key":"10.1016\/j.intimp.2022.109597_b0465","doi-asserted-by":"crossref","unstructured":"K.E. Burke, B. Kochar, J.R. Allegretti, R.W. Winter, P. Lochhead, H. Khalili, F.P. Colizzo, M.J. Hamilton, W.W. Chan, A.N. Ananthakrishnan, Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients with Inflammatory Bowel Diseases, Inflamm Bowel Dis. 27 (2021) 155\u2013161. https:\/\/doi.org\/10.1093\/ibd\/izaa278.","DOI":"10.1093\/ibd\/izaa278"},{"key":"10.1016\/j.intimp.2022.109597_b0470","doi-asserted-by":"crossref","unstructured":"M. Attauabi, A. Poulsen, K. Theede, N. Pedersen, L. Larsen, T. Jess, M.R. Hansen, M.K. Verner-Andersen, K. v. Haderslev, A. Berg L\u00f8drup, A. Molazahi, A. Neumann, A. Wase, J.B. Seidelin, J. Burisch, Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease\u2014A Danish Prospective Population-based Cohort Study, J Crohns Colitis. 15 (2021) 540\u2013550. https:\/\/doi.org\/10.1093\/ECCO-JCC\/JJAA205.","DOI":"10.1093\/ecco-jcc\/jjaa205"},{"key":"10.1016\/j.intimp.2022.109597_b0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fped.2021.607285","article-title":"Children With Inflammatory Bowel Disease in the COVID-19 Main Endemic Focus: The Lombardy Experience","volume":"9","author":"Sansotta","year":"2021","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.intimp.2022.109597_b0480","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/apt.16410","article-title":"Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study","volume":"54","author":"Meyer","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2022.109597_b0485","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3748\/wjg.v27.i12.1226","article-title":"Risk stratification and geographical mapping of Brazilian inflammatory bowel disease patients during the COVID-19 outbreak: Results from a nationwide survey","volume":"27","author":"Queiroz","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.intimp.2022.109597_b0490","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/jgh3.12498","article-title":"Care of inflammatory bowel disease patients during coronavirus disease-19 pandemic using digital health-care technology","volume":"5","author":"Ghoshal","year":"2021","journal-title":"JGH Open."},{"issue":"2020","key":"10.1016\/j.intimp.2022.109597_b0495","first-page":"276","article-title":"novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases","volume":"52","author":"Taxonera","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2022.109597_b0500","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.cgh.2020.04.071","article-title":"Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts","volume":"18","author":"Allocca","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.intimp.2022.109597_b0505","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1007\/s40520-021-01917-9","article-title":"Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease","volume":"33","author":"Calafat","year":"2021","journal-title":"Aging Clin. Exp. Res."},{"key":"10.1016\/j.intimp.2022.109597_b0510","doi-asserted-by":"crossref","unstructured":"L.A.A.P. Derikx, M.A. Lantinga, D.J. de Jong, W.A. van Dop, R.H. Creemers, T.E.H. R\u00f6mkens, J.M. Jansen, N. Mahmmod, R.L. West, A.C.I.T.L. Tan, A.G.L. Bodelier, M.H.P. Gorter, P.J. Boekema, E.R.C. Halet, C.S. Horjus, M.A. van Dijk, M.M.C. Hirdes, L.S.M. Epping Stippel, B. Jharap, M.W.M.D. Lutgens, M.G. Russel, L.P.L. Gilissen, S. Nauta, A.A. van Bodegraven, F. Hoentjen, Clinical Outcomes of Covid-19 in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study, J Crohns Colitis. 15 (2021) 529\u2013539. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa215.","DOI":"10.1093\/ecco-jcc\/jjaa215"},{"issue":"3","key":"10.1016\/j.intimp.2022.109597_b0515","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.dld.2020.12.012","article-title":"COVID-19 in IBD: The experience of a single tertiary IBD center","volume":"53","author":"Rizzello","year":"2021","journal-title":"Dig. Liver Dis."},{"issue":"11","key":"10.1016\/j.intimp.2022.109597_b0520","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1111\/jgh.15588","article-title":"COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry","volume":"36","author":"Queiroz","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109597_b0525","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1053\/j.gastro.2020.05.009","article-title":"SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California","volume":"159","author":"Gubatan","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2022.109597_b0530","doi-asserted-by":"crossref","unstructured":"R.H. Creemers, A.R. Ardabili, D.M. Jonkers, M.P.G. Leers, M.J. Romberg-Camps, M.J. Pierik, A.A. van Bodegraven, Severe COVID-19 in inflammatory bowel disease patients in a population-based setting, PLoS One. 16 (2021) e0258271. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0258271.","DOI":"10.1371\/journal.pone.0258271"},{"key":"10.1016\/j.intimp.2022.109597_b0535","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1053\/j.gastro.2020.04.043","article-title":"Characteristics and Prognosis of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic in the Basque Country (Spain)","volume":"159","author":"Rodr\u00edguez-Lago","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2022.109597_b0540","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1053\/j.gastro.2020.03.062","article-title":"Uneventful Course in Patients With Inflammatory Bowel Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Outbreak in Northern Italy","volume":"159","author":"Norsa","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2022.109597_b0545","doi-asserted-by":"crossref","unstructured":"C.P. Selinger, A. Fraser, P. Collins, M. Gunn, T.S. Chew, G. Kerry, K. v. Patel, M. Roysam, K. Bel Kok, A. Bancil, V. Hall, R. Cooney, L. Smith, H. Steed, J. Segal, A. Kent, J. Limdi, S. Sebastian, Impact of the coronavirus infectious disease (COVID-19) pandemic on the provision of inflammatory bowel disease (IBD) antenatal care and outcomes of pregnancies in women with IBD, BMJ Open Gastroenterol. 8 (2021) 1\u20136. https:\/\/doi.org\/10.1136\/bmjgast-2021-000603.","DOI":"10.1136\/bmjgast-2021-000603"},{"key":"10.1016\/j.intimp.2022.109597_b0550","doi-asserted-by":"crossref","unstructured":"M.D. Long, X. Zhang, J.D. Lewis, G.Y. Melmed, C.A. Siegel, E. Cerciello, A. Dobes, A. Weaver, L. Weisbein, M.D. Kappelman, Risks of Development of COVID-19 among Patients with Inflammatory Bowel Disease: A Comparative Assessment of Risk Factors for Incident Infection, Crohns Colitis 360. 4 (2022). https:\/\/doi.org\/10.1093\/CROCOL\/OTAC011.","DOI":"10.1093\/crocol\/otac011"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922010827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922010827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T12:07:51Z","timestamp":1719230871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922010827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":110,"alternative-id":["S1567576922010827"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109597","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thiopurine therapy in inflammatory bowel disease in the pandemic era: Safe or unsafe?","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109597","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109597"}}